Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sapropterin dihydrochloride (Kuvan®), hereafter referred to as sapropterin, is a synthetic formulation of the active 6R-isomer of tetrahydrobiopterin, a naturally occurring cofactor for phenylalanine hydroxylase. In the EU, sapropterin is approved for the treatment of hyperphenylalaninaemia in patients ≥4 years of age with tetrahydrobiopterin-responsive phenylketonuria (PKU) and in adults and children with tetrahydrobiopterin deficiency who have been shown to be responsive to such treatment. In the US, it is approved to reduce blood phenylalanine levels in patients with hyperphenylalaninaemia due to tetrahydrobiopterin-responsive PKU.
Oral sapropterin effectively lowers blood phenylalanine levels in a proportion of patients with PKU; to date, there are no published efficacy trials of the specific sapropterin formulation under review in patients with tetrahydrobiopterin deficiency. Sapropterin was well tolerated in patients with PKU, although longer-term tolerability data are required. Sapropterin is the first non-dietary treatment for patients with PKU that has been shown in randomized, double-blind trials to be effective in lowering blood phenylalanine levels. Thus, sapropterin provides a promising treatment option for patients with PKU who are tetrahydrobiopterin-responsive.
The mechanism of action of sapropterin in lowering blood phenylalanine levels in patients with PKU has not been fully elucidated, but appears to be related, in part, to its effect in augmenting and stabilizing mutant phenylalanine hydroxylases, resulting in increased clearance of phenylalanine from the body. In tetrahydrobiopterin deficiency, its mechanism of action is presumed to be secondary to replacement of endogenous tetrahydrobiopterin.
In healthy adults, orally-administered sapropterin is absorbed into the bloodstream,reaching maximum concentrations in 3–4 hours. It has a mean elimination half-life of ≈4 hours in healthy adults and, based on a population pharmacokinetic study, 6.7 hours in patients with tetrahydrobiopterin-responsive PKU. Age, from 9 to 49 years, had no effect on key pharmacokinetic parameters.
In an 8-day screening study in patients aged ≥8 years with PKU, ≈20% of patients responded to sapropterin 10mg/kg/day (i.e. were tetrahydrobiopterin responsive). Tetrahydrobiopterin-responsive patients from this study were entered into a randomized, double-blind, placebo-controlled trial in which they received sapropterin 10mg/kg/day or placebo. At the end of 6 weeks of treatment, sapropterin recipients experienced a significant 28% decrease from baseline in mean blood phenylalanine level, while there was no significant change in placebo recipients. The difference in mean blood phenylalanine level between sapropterin and placebo groups was statistically significant at −245 μmol/L. In an extension of this trial, significantly greater reductions in blood phenylalanine levels were observed with sapropterin dosages of 10 and 20 mg/kg/day than with sapropterin 5 mg/kg/day (each dose administered for 2 weeks), indicating a dose dependent effect. During 12 weeks of treatment with the sapropterin dosage individualized to the patient according to the earlier response to sapropterin 5, 10 or 20 mg/kg/day, reductions in plasma phenylalanine were observed in all dosage groups.
In a randomized, double-blind trial in children aged 4–12 years with tetrahydrobiopterin-responsive PKU, patients treated with sapropterin 20 mg/kg/day had reduced blood phenylalanine levels after 3 weeks of treatment. Over the full 10-week trial, sapropterin and placebo recipients experienced a significantly increased tolerance to dietary phenylalanine (20.9 mg/kg/day in sapropterin and 2.9mg/kg/day in placebo recipients).
Sapropterin was well tolerated in patients with PKU. In clinical trials in patients with PKU, the following adverse events were identified: headache, rhinorrhoea (both at a frequency of ≥10%), pharyngolaryngeal pain, nasal congestion, cough, diarrhoea, vomiting, abdominal pain and hypophenylalaninaemia (all at a frequency of ≥1% to <10%). There were no serious adverse events that were thought to be related to sapropterin treatment.
- Scriver CR, Levy H, Donlon J. Chapter 77. Hyperphenyla-laninaemia: phenylalanine hydroxylase deficiency. In: Metabolic and molecular bases of inherited disease [on-line]. Available from URL.http://www.ommbid.com/OMMBID/the_online_metabolic_bases_of_inherited_disease/b/fulltoc [Accessed 2009 Jan 12]
- Blau N, Thöny B, Cotton RGH et al. Chapter 78. Disorders of tetrahydrobiopterin and related biogenic amines. In: Metabolic and molecular bases of inherited disease [online]. Available from URL. http://www.ommbid.com/OMMBID/the_online_metabolic_bases_of_inherited_disease/b/fulltoc [Accessed 2009 Jan 12]
- Michals-Matalon, K (2008) Sapropterin dihydrochloride, 6-R-L-erythro-5,6,7,8-tetrahydrobiopterin, in the treatment of phenylketonuria. Expert Opin Investig Drugs 17: pp. 245-51 CrossRef
- Gramer, G, Burgard, P, Garbade, SF (2007) Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia. J Inherit Metab Dis 30: pp. 556-62 CrossRef
- Longo, N Chapter 352. Inherited disorders of amino acid metabolism and storage. In: Braunwald, E eds. (2001) Harrison's principles of internal medicine (15th edition). McGraw-Hill, New York, pp. 2301-5
- Guldberg, P, Rey, F, Zschocke, J (1998) A European multicentre study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. American J Hum Genet 63: pp. 71-9 CrossRef
- Surtees, R, Blau, N (2000) The neurochemistry of phenylketonuria. Eur J Pediatr 159: pp. S109-13 CrossRef
- Baulny, HO, Abadie, V, Feillet, F (2007) Management of phenylketonuria and hyperphenylalaninemia. J Nutr 137: pp. 1561-3S
- Weglage, J, Pietsch, M, Feldmann, R (2001) Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 49: pp. 532-6 CrossRef
- Kure, S, Hou, DC, Ohura, T (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135: pp. 375-8 CrossRef
- Muntau, AC, Röschinger, W, Habich, M (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 347: pp. 2122-32 CrossRef
- Pey, AL, Martinez, A (2007) Tetrahydrobiopterin for patients with phenylketonuria. Lancet 370: pp. 462-3 CrossRef
- US FDA. Sapropterin dihydrochloride: prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/022181lbl.pdf [Accessed 2008 Aug 5]
- Asubio Pharma Co Ltd. Asubio Pharma's inherited metabolic disease agent Biopten® receives approval for additional indication, 2008 Jul 16 [online media release]. Available from URL: http://www.daiichisankyo.com/4less/cgi-bin/cs4view_obj.php/b_newsrelease_n1_eng/554/080716_001v1-e.pdf [Accessed 2009 Mar 13]
- European Medicines Agency. Kuvan®: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/kuvan/H-943-PI-en.pdf [Accessed 2009 Jan 18]
- Matalon, R, Koch, R, Michals-Matalon, K (2004) Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med 6: pp. 27-32 CrossRef
- Erlandsen, H, Stevens, RC (2001) A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperpheny-lalaninemia and phenylketonuria. J Inherit Metab Dis 24: pp. 213-30 CrossRef
- Erlandsen, H, Pey, AL, Gámez, A (2004) Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A 101: pp. 16903-8 CrossRef
- Ormazabal, A, Vilaseca, MA, Pérez-Dueñas, B (2005) Platelet serotonin concentrations in PKU patients under dietary control and tetrahydrobiopterin treatment. J Inherit Metab Dis 28: pp. 863-70 CrossRef
- Feillet, F, Clarke, L, Meli, C (2008) Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin Pharmacokinet 47: pp. 817-25 CrossRef
- US FDA Centre for Drug Evaluation and Research. Sapropterin dihydrochloride review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2007/022181s000_MedR_P1.pdf [Accessed 2008 Aug 1]
- Burton, BK, Grange, DK, Milanowski, A (2007) The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis 30: pp. 700-7 CrossRef
- Levy, HL, Milanowski, A, Chakrapani, A (2007) Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 370: pp. 504-10 CrossRef
- Lee, P, Treacy, EP, Crombez, E (2008) Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet Part A 146A: pp. 2851-9 CrossRef
- Trefz FK, Burton BK, Longo N, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. Epub 2009 Mar 2
- US National Institutes of Health. Phenylketonuria: screening and management (National Institutes of Health Consensus Development Conference Statement October 16–18, 2000) [online]. Available from URL: http://consensus.nih.gov/2000/2000Phenylketonuria113html.htm [Accessed 2008 Oct 28]
- Waisbren, SE, Noel, K, Fahrbach, K (2007) Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 92: pp. 63-70 CrossRef
- European Medicines Agency. Committee for Medicinal Products for Human Use assessment report for Kuvan [online]. Available from URL: http://www.emea.eu/humandocs/PDFs/EPAR/kuvan/H-943-en6.pdf [Accessed 2009 Feb 25]
- Blau, N (2008) Defining tetrahydrobiopterin (BH4) responsiveness in PKU. J Inherit Metab Dis 31: pp. 2-3 CrossRef
- Doggrell, SA (2008) Is sapropterin treatment suitable for all subjects with phenylketonuria?. Expert Opin Pharmacother 9: pp. 145-7 CrossRef
- BioMarin Pharmaceutical. Study of phenoptin in subjects with phenylketonuria who have participated in protocols PKU-004 or PKU-006 [ClinicalTrials.gov identifier NCT00332189]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Mar 5]
- Shintaku, H, Kure, S, Ohura, T (2004) Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr Res 55: pp. 425-30 CrossRef
- Lambruschini, N, Pérez-Dueñas, B, Vilaseca, MA (2005) Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 86: pp. S54-60 CrossRef
- Hennermann, JB, Bührer, C, Blau, N (2005) Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol Genet Metab 86: pp. S86-90 CrossRef
- Koch, R, Hanley, W, Levy, H (2003) The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics 112: pp. 1523-9
- Trefz, FK, Blau, N (2003) Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112: pp. 1566-9
Volume 69, Issue 4 , pp 461-476
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors